Nanobiotix S.A. (EPA:NANO)
18.22
-0.30 (-1.62%)
Oct 7, 2025, 5:35 PM CET
Nanobiotix Revenue
In the year 2024, Nanobiotix had annual revenue of -7.19M EUR, down -119.86%. Nanobiotix had revenue of -16.48M in the half year ending December 31, 2024, a decrease of -578.07%.
Revenue
-7.19M
Revenue Growth
-119.86%
P/S Ratio
86.47
Revenue / Employee
98.63K
Employees
108
Market Cap
878.47M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | -7.19M | -43.40M | -119.86% |
Dec 31, 2023 | 36.21M | 31.43M | 658.12% |
Dec 31, 2022 | 4.78M | 2.13M | 80.43% |
Dec 31, 2021 | 2.65M | 322.00K | 13.85% |
Dec 31, 2020 | 2.33M | -216.00K | -8.50% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
EssilorLuxottica Société anonyme | 27.24B |
Sanofi | 45.74B |
Sartorius Stedim Biotech | 2.90B |
bioMérieux | 4.12B |
Eurofins Scientific SE | 7.14B |
Ipsen | 3.76B |
ABIVAX Société Anonyme | 6.02M |
Virbac | 1.43B |
Nanobiotix News
- 5 days ago - Nanobiotix (NBTX) Sees Stock Rise on Promising Cancer Drug Trial Results - GuruFocus
- 5 days ago - Nanobiotix gains after early-stage trial data for J&J-partnered cancer drug - Seeking Alpha
- 5 days ago - Top 2 Health Care Stocks That May Keep You Up At Night This Month - Benzinga
- 6 days ago - NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer - GlobeNewsWire
- 6 days ago - Nanobiotix S.A. GAAP EPS of -€0.11, revenue of €26.6M - Seeking Alpha
- 7 days ago - NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results - GlobeNewsWire
- 7 days ago - Nanobiotix-J&J Therapy Shows Promise In Tough Head And Neck Cancer - Benzinga
- 8 days ago - NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC - GlobeNewsWire